Next-Generation CDK Inhibitors in Breast Cancer: Expanding the Therapeutic Landscape beyond CDK4/6 Inhibitors
{{output}}
Background: The efficacy of CDK4/6 inhibitors in hormone receptor-positive breast cancer has catalyzed the exploration of other cyclin-dependent kinases (CDKs) as therapeutic targets. Numerous CDK family members are aberrantly ac... ...
